The stock of Illumina, Inc. (NASDAQ:ILMN) is a huge mover today! About 1.46 million shares traded hands or 5.04% up from the average. Illumina, Inc. (NASDAQ:ILMN) has declined 5.83% since March 15, 2016 and is downtrending. It has underperformed by 11.32% the S&P500.
The move comes after 8 months positive chart setup for the $22.14 billion company. It was reported on Oct, 18 by Barchart.com. We have $224.26 PT which if reached, will make NASDAQ:ILMN worth $11.51 billion more.
Illumina, Inc. (NASDAQ:ILMN) Ratings Coverage
Out of 22 analysts covering Illumina Inc (NASDAQ:ILMN), 7 rate it a “Buy”, 1 “Sell”, while 14 “Hold”. This means 32% are positive. Illumina Inc has been the topic of 45 analyst reports since July 22, 2015 according to StockzIntelligence Inc. On Tuesday, April 19 the stock rating was maintained by Morgan Stanley with “Equal-Weight”. The stock of Illumina, Inc. (NASDAQ:ILMN) earned “Equal-Weight” rating by Morgan Stanley on Tuesday, May 3. The rating was maintained by Barclays Capital on Tuesday, April 19 with “Equal-Weight”. Deutsche Bank initiated Illumina, Inc. (NASDAQ:ILMN) on Thursday, January 7 with “Hold” rating. The company was upgraded on Wednesday, August 26 by Citigroup. The stock has “Market Perform” rating given by Wells Fargo on Thursday, January 7. As per Tuesday, April 19, the company rating was downgraded by Cantor Fitzgerald. The rating was maintained by Canaccord Genuity with “Hold” on Tuesday, October 11. The firm has “Buy” rating given on Wednesday, July 22 by Canaccord Genuity. Canaccord Genuity downgraded Illumina, Inc. (NASDAQ:ILMN) on Thursday, February 4 to “Hold” rating.
According to Zacks Investment Research, “Illumina Inc. is a leading developer of next-generation tools for the large-scale analysis of genetic variation and function. The company’s tools will provide information that could be used to improve drugs and therapies, customize diagnoses and treatment, and cure disease. The company is developing a comprehensive line of products that can address the scale of experimentation and the breadth of functional analysis required to achieve the goals of molecular medicine.”
Insitutional Activity: The institutional sentiment decreased to 1.1 in Q2 2016. Its down 0.03, from 1.13 in 2016Q1. The ratio turned negative, as 66 funds sold all Illumina, Inc. shares owned while 150 reduced positions. 46 funds bought stakes while 191 increased positions. They now own 137.98 million shares or 3.82% less from 143.46 million shares in 2016Q1.
Sumitomo Mitsui Asset Mngmt Company Ltd reported 11,158 shares or 0.05% of all its holdings. Checchi Capital Advisers Limited Liability Corporation accumulated 958 shares or 0.02% of the stock. Stone Run Ltd Limited Liability Company reported 5,950 shares or 0.54% of all its holdings. Capital Intll Ca owns 22,300 shares or 0.38% of their US portfolio. Adage Cap Prtnrs Group Inc Limited Liability Corporation has 218,700 shares for 0.08% of their US portfolio. Next Fincl Group Inc has 3,006 shares for 0.13% of their US portfolio. Page Arthur B holds 0.23% of its portfolio in Illumina, Inc. (NASDAQ:ILMN) for 1,634 shares. Alliancebernstein Ltd Partnership accumulated 1.06 million shares or 0.13% of the stock. Teachers Advsrs holds 0.09% or 379,900 shares in its portfolio. Gateway Investment Advisers Limited Liability owns 126,180 shares or 0.15% of their US portfolio. The Texas-based Cullen Frost Bankers has invested 0.04% in Illumina, Inc. (NASDAQ:ILMN). Arrowgrass Partners (Us) L P holds 0.02% of its portfolio in Illumina, Inc. (NASDAQ:ILMN) for 14,750 shares. Dubuque Bank And Tru reported 14 shares or 0% of all its holdings. Moreover, Susquehanna Group Llp has 0% invested in Illumina, Inc. (NASDAQ:ILMN) for 52,824 shares. Gam Hldg Ag, a Switzerland-based fund reported 10,467 shares.
Insider Transactions: Since April 27, 2016, the stock had 0 buys, and 28 insider sales for $17.42 million net activity. On Thursday, July 14 the insider BOWMAN A BLAINE sold $735,705. 10,000 Illumina, Inc. (NASDAQ:ILMN) shares with value of $1.50M were sold by FLATLEY JAY T. $102,748 worth of Illumina, Inc. (NASDAQ:ILMN) was sold by BRADBURY DANIEL. $726,750 worth of Illumina, Inc. (NASDAQ:ILMN) was sold by EASTHAM KARIN on Wednesday, June 1. Shares for $533,672 were sold by WHITFIELD ROY A. $21,156 worth of Illumina, Inc. (NASDAQ:ILMN) was sold by Dadswell Charles. HENRY CHRISTIAN O had sold 2,141 shares worth $301,532 on Tuesday, May 17.
More recent Illumina, Inc. (NASDAQ:ILMN) news were published by: Foxbusiness.com which released: “3 Warning Signs from Illumina, Inc.’s Q3 Preview” on October 12, 2016. Also Investorplace.com published the news titled: “3 Stocks to Watch Tuesday: Illumina, Inc. (ILMN), Seagate Technology PLC (STX …” on October 11, 2016. Investorplace.com‘s news article titled: “Why Alcoa Inc (AA), Illumina, Inc. (ILMN) and Seagate Technology PLC (STX) Are …” with publication date: October 11, 2016 was also an interesting one.
ILMN Company Profile
Illumina, Inc. (Illumina), incorporated on May 16, 2000, offers sequencing and array solutions for genetic analysis. The Company’s services and products serve clients in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. The Company’s clients include genomic research centers, academic institutions, government laboratories and hospitals, as well as pharmaceutical, biotechnology, agrigenomics and commercial molecular diagnostic laboratories, and consumer genomics companies. Illumina provides sample-to-answer solutions to its clients in various areas of translational and clinical genomics, such as reproductive and genetic health, and oncology. Illumina provides reproductive-health solutions, including preimplantation genetic screening and diagnosis (PGS and PGD), noninvasive prenatal testing (NIPT), and neonatal and genetic health testing. The Company’s BaseSpace platform, which can be hosted onsite or in the cloud, integrates directly with its sequencing instruments, facilitates data sharing, provides data-storage solutions and streamlines analysis. It has activities in the United States, Europe, Asia-Pacific and other markets.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.